[Evaluation of two commercial enzyme immunoassays for diagnosis of hepatitis C in the conditions of a virology laboratory].
BACKGROUND
Most studies which evaluate antibody detection assays are conducted on blood donors specimens, i.e healthy individuals. Sera collected in patients, vs healthy individuals, can make serological tests difficult because of possible non specific reactions interfering with serological tests. The aim of this work was to compare the specificity and the sensitivity of two commercial automated assays for the detection of hepatitis C virus antibody, Monolisa anti-HCV Plus on the Evolis automate (Biorad) and Axsym anti-HCV 3.0 (Abbott).


METHODS
The prospective study of specificity included 2020 routine serum samples sent to our virology laboratory. The sensitivity was established with eight commercially available HCV seroconversion panels.


RESULTS
The Monolisa and the Axsym assays showed a specificity of 99.64 and 99.12%, respectively. Of 49 specimens from eight commercially available HCV seroconversion panels, the number of positive results was 21 and 24 for the two tests, respectively.


CONCLUSIONS
A statistical analysis of specificity and sensitivity results proved no significant difference between the two tests. Nevertheless, the Monolisa kits could be preferred for its more homogeneous sensitivity than the Axsym test and for its apparent better specificity. The final choice of a kit should also take into account the easiness to perform and an optimal integration in the usual practice of the concerned laboratory.
Zachary
P
P
Institut de virologie faculté de médecine, 3, rue Koeberlé 67000 Strasbourg, France. procrastisme@yahoo.fr
Ullmann
M
M
Djeddi
S
S
Wendling
M-J
MJ
Schvoerer
E
E
Stoll-Keller
F
F
Gut
J-P
JP
D001331:Automation; D016174:Hepacivirus / Q000302:isolation & purification*; D006526:Hepatitis C / Q000097:blood / Q000175:diagnosis*; D006801:Humans; D007124:Immunoenzyme Techniques; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity